{
    "nctId": "NCT00702949",
    "briefTitle": "Pregabalin in Treating Women With Hot Flashes",
    "officialTitle": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hot Flashes",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 207,
    "primaryOutcomeMeasure": "Numerical Change From Baseline in Hot Flash Score at Treatment Week 6 (Positive Numbers to Represent Increases and Negative Numbers to Represent Decreases).",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meeting 1 of the following criteria:\n\n  * History of breast cancer (currently without malignant disease)\n  * No history of breast cancer, but patient wishes to avoid estrogen due to a perceived increased risk of breast cancer\n* Bothersome hot flashes (defined by their occurrence \u2265 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)\n* Presence of hot flashes for \u2265 1 month prior to study entry\n\nPATIENT CHARACTERISTICS:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Life expectancy \u2265 6 months\n* Able to complete questionnaire(s) by themselves or with assistance\n* Women of childbearing potential not eligible (per the judgment of the attending clinician)\n* Serum creatinine \u2264 1.5 times upper limit of normal\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior gabapentin or pregabalin\n* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents\n\n  * Vaginal estrogen is allowed if used for the past month and not planned to be discontinued\n* Concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab \\[Herceptin\u00ae\\]) allowed in patients with no evidence of disease\n* Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period\n* No concurrent or planned use of other agents for hot flashes except for any of the following:\n\n  * Stable dose of vitamin E is allowed as long as agent was started \\> 30 days prior to study initiation and is to be continued throughout the study period\n  * Soy is allowed, if it is planned to be continued at the same dose during the study period\n  * Stable dose of antidepressants is allowed as long as it was started \\> 30 days prior to study initiation and is to be continued at a stable dose throughout the study period",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}